Related Experiment Video
Updated: May 5, 2026

Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Mechanical Circulatory Support on Coronary Artery Bypass Grafting for Advanced Ischemic Cardiomyopathy: State of the
Erik J Orozco-Hernandez1, James E Davies1, Sasha Anne Still1
1Division of Cardiothoracic Surgery, Department of Cardiac Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Insights
Mechanical circulatory support (MCS) can aid high-risk patients undergoing coronary artery bypass grafting (CABG) for ischemic cardiomyopathy. Careful selection and timing of MCS are crucial for optimizing outcomes and mitigating risks.
Area of Science:
- Cardiology
- Cardiac Surgery
- Mechanical Circulatory Support
Background:
- Ischemic cardiomyopathy involves coronary artery disease and left ventricular dysfunction (ejection fraction ≤ 40%).
- Myocardial tissue in ischemic cardiomyopathy is heterogeneous, comprising normal, stunned, hibernating, and scarred regions.
- Isolated assessments of myocardial viability and ischemia are insufficient for guiding coronary artery bypass grafting (CABG) decisions.
Purpose of the Study:
- To review indications and criteria for mechanical circulatory support (MCS) in advanced ischemic cardiomyopathy patients.
- To discuss various MCS devices for preoperative or intraoperative support.
- To examine technical considerations, advantages, disadvantages, and complications of MCS.
Main Methods:
- Review of current literature on mechanical circulatory support in ischemic cardiomyopathy.
- Analysis of factors influencing the decision for MCS, including clinical presentation, viability, hemodynamics, and imaging.
- Evaluation of preoperative optimization strategies involving MCS.
Main Results:
- Preoperative MCS can mitigate the impact of cardiopulmonary bypass, preserve end-organ perfusion, and reduce vasopressor needs.
- Integrating anatomical, morphological, functional, and hemodynamic data aids precise MCS selection and timing.
- The risk-benefit ratio of MCS requires careful consideration due to potential complications.
Conclusions:
- Judicious use of MCS can enhance CABG safety in high-risk patients with ischemic cardiomyopathy.
- Further robust, long-term prospective studies are needed to establish the definitive clinical impact of MCS.
- Optimizing MCS selection and timing is critical for improving outcomes in this patient population.
Abstract:
Ischemic cardiomyopathy is defined as coronary artery disease accompanied by left ventricular dysfunction with an ejection fraction equal to or less than 40%. The substrate of ischemic cardiomyopathy is heterogeneous, characterized by the coexistence of normal, stunned, hibernating, and scarred myocardium within the same myocardial region. Altogether, these components may represent different phases of a single pathological process. It is well-established that the assessment of isolated myocardial viability and ischemia alone has failed to reliably guide the indication for coronary artery bypass grafting (CABG). CABG in patients with low ejection fraction carries a significant risk of perioperative mortality and morbidity, largely related to the development of postcardiotomy shock. Preoperative optimization with pharmacologic or mechanical circulatory support (MCS) is often essential; the decision requires integrating multiple complex factors, including clinical presentation, response to optimization therapy, myocardial viability, the presence of hibernating or scarred myocardium, left ventricular end-systolic volume index, coronary angiography findings, hemodynamic assessment, and the Pulmonary Arterial Pressure Index score. A preoperative evaluation that incorporates anatomical, morphological, functional, and hemodynamic domains enables more precise selection and timing of MCS. Preemptive left ventricular unloading mitigates the physiological impact of cardiopulmonary bypass, preserves end-organ perfusion, and reduces the need for high-dose vasopressors. However, the risk-benefit ratio remains uncertain and may be associated with serious complications. Careful judgment regarding the indications for MCS has the potential to enhance the safety of CABG in high-risk patients, but robust, long-term, prospective studies are needed to determine its true impact on clinical outcomes. In this review, we will examine the indications and criteria for the use of MCS in patients with advanced ischemic cardiomyopathy, as well as the various devices available for preoperative or intraoperative support, including technical considerations, advantages and disadvantages, and associated complications.
More Related Videos
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy

